Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23951365 | 1.00 | USP2 (0.48) | USP2SMN1; SMN2RECQLNR1H2USP30 | |
| SCHEMBL23924132 | 1.00 | USP2 (0.48) | USP2SMN1; SMN2RECQLNR1H2USP30 | |
| SCHEMBL3449731 | 0.90 | NR1H2 (0.48) | USP2SMN1; SMN2RECQLNR1H2USP30 | |
| SCHEMBL13110519 | 0.90 | NR1H2 (0.48) | USP2SMN1; SMN2RECQLNR1H2USP30 | |
| SCHEMBL23951599 | 0.87 | PDE4B (0.46) | USP2SMN1; SMN2RECQLNR1H2USP30 | |
| SCHEMBL23951358 | 0.86 | PDE4B (0.46) | USP2SMN1; SMN2RECQLNR1H2GPR119 | |
| SCHEMBL23923813 | 0.86 | PDE4B (0.46) | USP2SMN1; SMN2RECQLNR1H2GPR119 | |
| SCHEMBL23923814 | 0.86 | PDE4B (0.46) | USP2SMN1; SMN2RECQLNR1H2GPR119 | |
| SCHEMBL5311614 | 0.83 | NR1H2 (0.54) | USP2SMN1; SMN2RECQLNR1H2USP30 | |
| SCHEMBL37879 | 0.83 | NR1H2 (0.54) | USP2SMN1; SMN2RECQLNR1H2USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220213061-A9 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | TES PHARMA S.R.L. (IT) | 2022-07-07 | — | — | US | disclosed |
| US-20210323942-A1 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | TES PHARMA S R L (IT) | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213061-A9 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | NR2E3, NR2F2, NR2C2 | USP2 1570/4885SMN1; SMN2 252/4885RECQL 3206/4885 |
| US-20210323942-A1 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | NR2E3, NR2F2, NR2C2 | USP2 1570/4885SMN1; SMN2 252/4885RECQL 3206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.